Kohno, Kimitoshi

Cisplatin Resistance Associated with PARP Hyperactivation

Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research

PARP inhibition in cancer therapyCell death mechanisms and regulation

Cited by 176

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

Yamamoto, C., Basaki, Y., Kawahara, A., Nakashima, K., Kage, M., Izumi, H., Kohno, K., Uramoto, H., Yasumoto, K., Kuwano, M., et al. (2010) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 155

Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist1 to Suppress Cancer Cell Growth

Shiota, M., Izumi, H., Tanimoto, A., Takahashi, M., Miyamoto, N., Kashiwagi, E., Kidani, A., Hirano, G., Masubuchi, D., Fukunaka, Y., et al. (2009) · Cancer Research

Cancer-related Molecular PathwaysCell death mechanisms and regulation

Cited by 134

Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction

Wu, Y., Wang, K.-Y., Li, Z., Liu, Y.-P., Izumi, H., Uramoto, H., Nakayama, Y., Ito, K.-I., & Kohno, K. (2014) · Journal of Experimental & Clinical Cancer Research

Cancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents

Cited by 17